This HTML5 document contains 160 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://dx.doi.org/10.1002/
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q51066747
rdf:type
wikibase:Item
schema:description
artykuł naukowy vitenskapelig artikkel article scientifique artigo científico videnskabelig artikel bài báo khoa học articol științific ১৫ এপ্রিল ২০১৩-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ מאמר מדעי tudományos cikk vetenskaplig artikel 2013 nî lūn-bûn 2013年學術文章 2013年学术文章 artikulong pang-agham 2013年の論文 artículu científicu scientific article published on 15 April 2013 vědecký článek επιστημονικό άρθρο наукова стаття, опублікована у квітні 2013 2013年學術文章 2013年学术文章 wissenschaftlicher Artikel artigo científico scientific article published on 15 April 2013 บทความทางวิทยาศาสตร์ vedecký článok სამეცნიერო სტატია 2013年学术文章 мақолаи илмӣ مقالة علمية نشرت في 15 أبريل 2013 научна статия scienca artikolo article científic 2013年学术文章 teaduslik artikkel 2013年學術文章 articolo scientifico vitskapeleg artikkel wetenschappelijk artikel 2013년 논문 artigo científico article scientific 2013年學術文章 bilimsel makale 2013年学术文章 научни чланак tieteellinen artikkeli artikull shkencor научни чланак 2013年學術文章 naučni članak artículo científico publicado en 2013 artikel ilmiah scientific article published on 15 April 2013 научная статья 2013年学术文章
p:P577
wds:Q51066747-0D1B2DA0-1D4B-4AD7-97CF-957B12CEDA85
wdt:P577
2013-04-15T00:00:00Z
p:P407
wds:Q51066747-2D4011F0-7594-41DD-B46E-D38A63805F6D
wdt:P407
wd:Q1860
p:P2860
wds:Q51066747-8DBCA11C-0AF9-40A8-94E6-7C0E18BE3C98 wds:Q51066747-574FF923-C449-472A-9BC7-50C7C5E1DDFF wds:Q51066747-6E8A1C6C-7D4D-48F8-9A97-1A043D16D673 wds:Q51066747-7F8302C7-5FD4-445F-B7E3-71B3C1B7E88D wds:Q51066747-8688C21D-1CCC-467B-A997-F44B42FBD7C8 wds:Q51066747-CB2D68F7-1E9D-4FB3-BAE3-2DB31CC98971 wds:Q51066747-CFA7866C-0AB7-4A29-B5E8-F081AC8287CA wds:Q51066747-E72FCB26-FF21-4663-8664-B08BB8BF70D5 wds:Q51066747-A3C534D9-AD77-4BAD-B75A-B6DCE4D770D5 wds:Q51066747-A46C1C01-D71B-4F43-9F6B-2F760AB27063 wds:Q51066747-B0EECCD5-9600-44A9-A834-148BD1116AEF wds:Q51066747-B9DFDB41-9114-423F-B5E7-02BAAC999AA1 wds:Q51066747-F421968C-0294-4C83-BA52-126A144243AC wds:Q51066747-F79C338F-BE5F-49AE-A45C-8EC0C8DE1D63 wds:Q51066747-3F462C07-1D96-44DA-919A-836118F0DA94 wds:Q51066747-40B3D6EF-9EFF-4CE6-BFD0-51A25B7F126D wds:Q51066747-4FFC2A67-8C5C-4D30-8E4C-1687716F1434 wds:Q51066747-53DED164-4D33-4D7D-88AB-517CFE2E49B9
wdt:P2860
wd:Q34499046 wd:Q37953072 wd:Q37278365 wd:Q84840694 wd:Q82270514 wd:Q27860904 wd:Q33381250 wd:Q45267615 wd:Q85202032 wd:Q28741842 wd:Q36344264 wd:Q44883868 wd:Q37823790 wd:Q35776264 wd:Q46180496 wd:Q78515149 wd:Q37807628 wd:Q36613654
p:P2093
wds:Q51066747-ADCD8196-B651-4480-93F7-E5F9EF4ED3D4 wds:Q51066747-892D2346-BED5-43D5-98CD-CA42059A5D87 wds:Q51066747-2252276C-9FD6-4C91-AEEA-16EDF43C5D95 wds:Q51066747-6AD3ACEC-7FC9-4279-8D62-21F6CAD2937A
wdt:P2093
Antoine Italiano Charles Fournier Jacques-Olivier Bay Eric Gauthier
rdfs:label
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO). Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group
skos:prefLabel
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
schema:name
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO).
p:P50
wds:Q51066747-EDFBEF36-3FAA-455D-94C7-B73EC21A8C96 wds:Q51066747-CAF4C748-A2E8-4F6C-A806-2E3719EE1F75 wds:Q51066747-88299BB9-433B-473C-9F75-A85F53CABD01 wds:Q51066747-93FA9CAE-24F2-4866-8646-FB0283C9592F wds:Q51066747-9B2111E0-D707-40BC-8C1B-6F68FD9E2ABE wds:Q51066747-9DBE15B0-8481-4F55-A80D-8930507C85B0 wds:Q51066747-93D420AB-0B43-43F0-A8BA-54976AC4341D wds:Q51066747-F0BC09A4-CF86-4B9E-A55F-8C12C5BF1196 wds:Q51066747-F796145F-5B3B-44EB-B808-ABF6816BACFF wds:Q51066747-23693DC9-A8FC-416B-91D1-408B748F41A0 wds:Q51066747-B79D5190-924A-4168-8983-52F76CA8F040 wds:Q51066747-BBC11373-7446-4C5C-B847-36CBFC528B0A
wdt:P50
wd:Q58128767 wd:Q33241280 wd:Q90030025 wd:Q116794133 wd:Q114440231 wd:Q89340670 wd:Q91058817 wd:Q43200541 wd:Q56381073 wd:Q37995869 wd:Q37842284
p:P1476
wds:Q51066747-D022C4E4-7F1F-4D63-973C-7A00FF4D9C39
wdt:P1476
Sorafenib in patients with progressive epithelioid hemangioendothelioma: a phase 2 study by the French Sarcoma Group (GSF/GETO)
p:P304
wds:Q51066747-E84DB1FF-3FB8-41B7-884C-E7A33EB9744D
wdt:P304
2639-2644
p:P31
wds:Q51066747-7D71D8E9-90C3-4D87-86CE-9A23333EF224
wdt:P31
wd:Q13442814
p:P921
wds:Q51066747-8CB85BBE-903A-4E79-9497-05D168F61957
wdt:P921
wd:Q5710984
p:P698
wds:Q51066747-71D7FA3E-5EC1-43BE-939C-647314AE8B97
wdtn:P698
n10:23589078
wdt:P698
23589078
p:P1433
wds:Q51066747-AA8006F9-7F1A-4B5A-AEEA-8E000225C2D3
wdt:P1433
wd:Q326041
p:P433
wds:Q51066747-F26320B0-1259-4818-AB1B-C719DBD10B6D
p:P478
wds:Q51066747-9DBC1B5E-A209-468E-AFE6-26DA8076EAED
wdt:P433
14
wdt:P478
119
p:P356
wds:Q51066747-EFA04836-56C6-4B65-91C8-E0C44303E2A9
wdtn:P356
n7:CNCR.28109
wdt:P356
10.1002/CNCR.28109
p:P8608
wds:Q51066747-46221445-1B44-4BE5-A2EB-D1030A5B7FA3
wdt:P8608
release_4ds2lknpejfepiyoasj2kkzhym
p:P5875
wds:Q51066747-1ADEF70D-21E6-4289-B94B-89C9D79AB6C9
wdt:P5875
236185660